Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children's Oncology Group (COG) New Agents for Ewing Sarcoma Task Force.
Ewing sarcoma
clinical trials
metastasis
relapse
therapy
Journal
F1000Research
ISSN: 2046-1402
Titre abrégé: F1000Res
Pays: England
ID NLM: 101594320
Informations de publication
Date de publication:
2019
2019
Historique:
accepted:
10
04
2019
entrez:
30
4
2019
pubmed:
30
4
2019
medline:
2
6
2020
Statut:
epublish
Résumé
Ewing sarcoma is a small round blue cell malignancy arising from bone or soft tissue and most commonly affects adolescents and young adults. Metastatic and relapsed Ewing sarcoma have poor outcomes and recurrences remain common. Owing to the poor outcomes associated with advanced disease and the need for a clear research strategy, the Children's Oncology Group Bone Tumor Committee formed the New Agents for Ewing Sarcoma Task Force to bring together experts in the field to evaluate and prioritize new agents for incorporation into clinical trials. This group's mission was to evaluate scientific and clinical challenges in moving new agents forward and to recommend agents and trial designs to the Bone Tumor Committee. The task force generated a framework for vetting prospective agents that included critical evaluation of each drug by using both clinical and non-clinical parameters. Representative appraisal of agents of highest priority, including eribulin, dinutuximab, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, anti-angiogenic tyrosine kinase inhibitors, and poly-ADP-ribose polymerase (PARP) inhibitors, is described. The task force continues to analyze new compounds by using the paradigm established.
Identifiants
pubmed: 31031965
doi: 10.12688/f1000research.18139.1
pmc: PMC6468706
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : K12 CA086913
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180886
Pays : United States
Déclaration de conflit d'intérêts
No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.
Références
J Clin Oncol. 2010 Jul 10;28(20):3284-91
pubmed: 20547982
Mol Cancer Ther. 2008 Jul;7(7):2003-11
pubmed: 18645010
Pediatr Blood Cancer. 2018 Aug;65(8):e27077
pubmed: 29693796
Cancer Cell. 2018 Feb 12;33(2):202-216.e6
pubmed: 29358035
Nature. 1993 Dec 16;366(6456):704-7
pubmed: 8259215
Rare Tumors. 2015 May 21;7(2):5992
pubmed: 26266019
Cancer Res. 2005 Jun 1;65(11):4633-44
pubmed: 15930281
Clin Cancer Res. 2015 Feb 15;21(4):819-32
pubmed: 25500058
Pediatr Blood Cancer. 2016 Oct;63(10):1780-5
pubmed: 27304202
Br J Cancer. 1992 Feb;65(2):287-91
pubmed: 1739631
Oncoimmunology. 2015 Apr 27;5(1):e1025194
pubmed: 26942051
Lancet Oncol. 2017 Nov;18(11):1493-1501
pubmed: 28988646
Cancer Res. 2004 Aug 15;64(16):5760-6
pubmed: 15313917
Pediatr Blood Cancer. 2015 May;62(5):759-65
pubmed: 25464386
Cancer Res. 2015 Dec 15;75(24):5176-5186
pubmed: 26627009
Cancer Res. 2016 Sep 1;76(17):5040-53
pubmed: 27364557
Clin Cancer Res. 2019 Jun 1;25(11):3417-3429
pubmed: 30723142
Cancer. 2010 Feb 1;116(3):749-57
pubmed: 20029966
J Clin Oncol. 2006 Jan 1;24(1):152-9
pubmed: 16382125
Cancer Res. 2012 Apr 1;72(7):1608-13
pubmed: 22287547
Cell Rep. 2014 Nov 6;9(3):829-41
pubmed: 25437539
Mol Cancer Ther. 2005 Jul;4(7):1086-95
pubmed: 16020666
Pediatr Blood Cancer. 2015 Apr;62(4):594-7
pubmed: 25630954
J Clin Oncol. 2004 Jul 15;22(14):2873-6
pubmed: 15254055
J Clin Oncol. 2015 Jul 10;33(20):2279-87
pubmed: 26033801
Clin Cancer Res. 2019 Feb 15;25(4):1343-1357
pubmed: 30397176
Cancer Cell. 2007 May;11(5):421-9
pubmed: 17482132
Cancer Res. 2001 Feb 1;61(3):1013-21
pubmed: 11221827
Mol Cancer Res. 2008 Jun;6(6):929-36
pubmed: 18567797
Nat Rev Drug Discov. 2010 Jan;9(1):17-8
pubmed: 20043026
Pediatr Blood Cancer. 2016 Mar;63(3):493-8
pubmed: 26579879
Oncogene. 2017 Jun 22;36(25):3505-3514
pubmed: 28135250
Nature. 2018 Mar 15;555(7696):387-391
pubmed: 29513652
Oncotarget. 2016 Apr 5;7(14):17616-30
pubmed: 26848860
Pediatr Blood Cancer. 2010 Dec 1;55(6):1224-6
pubmed: 20979180
Clin Cancer Res. 2018 Dec 1;24(23):6028-6039
pubmed: 30131386
Mol Cell Oncol. 2018 May 29;5(4):e1465014
pubmed: 30250915
Ann Oncol. 2018 Mar 1;29(3):766-771
pubmed: 29351570
Pediatr Blood Cancer. 2009 Mar;52(3):324-7
pubmed: 18989890
Lancet Oncol. 2017 Jul;18(7):946-957
pubmed: 28549783
N Engl J Med. 2003 Feb 20;348(8):694-701
pubmed: 12594313
Science. 2018 Aug 31;361(6405):
pubmed: 30166462
Clin Cancer Res. 2014 Aug 15;20(16):4200-9
pubmed: 24803583
Br J Cancer. 2012 Mar 13;106(6):1123-33
pubmed: 22374462
Acta Oncol. 2015 Jul;54(7):1063-4
pubmed: 25345493
Cancer Manag Res. 2018 Feb 01;10:207-216
pubmed: 29440930
J Clin Oncol. 2005 Jan 20;23(3):548-58
pubmed: 15659501
Br J Cancer. 1998 Sep;78(5):652-61
pubmed: 9744506
PLoS One. 2011 Apr 29;6(4):e19305
pubmed: 21559395
Oncotarget. 2015 Oct 6;6(30):30178-93
pubmed: 26337082
Clin Cancer Res. 2000 Oct;6(10):4110-8
pubmed: 11051264
J Natl Cancer Inst. 2011 Jun 22;103(12):962-78
pubmed: 21653923
Cell Cycle. 2012 Jul 15;11(14):2747-55
pubmed: 22751436
Nat Med. 2009 Jul;15(7):750-6
pubmed: 19584866
Int J Cancer. 2012 Nov 1;131(9):2153-64
pubmed: 22323082
Pediatr Blood Cancer. 2007 Feb;48(2):132-9
pubmed: 16317751
Pediatr Blood Cancer. 2013 Aug;60(8):1325-32
pubmed: 23553917
PLoS Med. 2007 Apr;4(4):e122
pubmed: 17425403
Sci Signal. 2017 Oct 03;10(499):
pubmed: 28974650
J Clin Oncol. 1998 Sep;16(9):3037-43
pubmed: 9738573
Pediatr Blood Cancer. 2018 Aug;65(8):e27066
pubmed: 29719113
Int J Cancer. 1987 Jul 15;40(1):81-6
pubmed: 3036723
Acta Oncol. 2018 Jul;57(7):958-964
pubmed: 29533113
Nat Rev Dis Primers. 2018 Jul 5;4(1):5
pubmed: 29977059
Cancer Rep (Hoboken). 2021 Apr;4(2):e1327
pubmed: 33314769
Lancet. 2012 May 19;379(9829):1879-86
pubmed: 22595799
J Clin Oncol. 2001 Aug 1;19(15):3463-9
pubmed: 11481351
Cancer Res. 2007 Jul 15;67(14):6675-84
pubmed: 17638877
Int J Urol. 2014 Nov;21(11):1183-4
pubmed: 25040171
Pediatr Blood Cancer. 2012 Sep;59(3):586-8
pubmed: 22190407
Pediatr Blood Cancer. 2009 Dec;53(6):1029-34
pubmed: 19637327
J Clin Oncol. 2012 Nov 20;30(33):4148-54
pubmed: 23091096
Pediatr Blood Cancer. 2012 Mar;58(3):372-9
pubmed: 21509928
Sarcoma. 2011;2011:957957
pubmed: 21512587
PLoS Genet. 2014 Jul 10;10(7):e1004475
pubmed: 25010205
Neoplasia. 2011 Feb;13(2):145-53
pubmed: 21403840
Clin Cancer Res. 2017 Jan 1;23(1):9-12
pubmed: 27780857
BMC Cancer. 2014 Nov 05;14:813
pubmed: 25374341
Biochim Biophys Acta. 2014 Apr;1845(2):266-76
pubmed: 24582852
Genet Med. 2017 Aug;19(8):955-958
pubmed: 28125078
Blood. 2007 May 15;109(10):4245-8
pubmed: 17264296
Oncogene. 2013 Oct 17;32(42):5089-100
pubmed: 23178492
Clin Cancer Res. 2000 Oct;6(10):4154-7
pubmed: 11051270
J Pediatr Hematol Oncol. 2013 Jul;35(5):356-60
pubmed: 23042020
Crit Rev Oncog. 2015;20(3-4):155-71
pubmed: 26349414
Clin Cancer Res. 1999 Nov;5(11):3617-31
pubmed: 10589779
Clin Sarcoma Res. 2015 Aug 28;5:20
pubmed: 26322224
Nature. 2012 Mar 28;483(7391):570-5
pubmed: 22460902
J Clin Oncol. 2018 Sep 6;:JCO2018782516
pubmed: 30188789
Oncotarget. 2017 May 23;8(21):34141-34163
pubmed: 27191748
Clin Cancer Res. 2007 Aug 15;13(16):4867-73
pubmed: 17699866
Clin Cancer Res. 2017 May 15;23(10):2433-2441
pubmed: 28432176
Pediatr Blood Cancer. 2006 Nov;47(6):795-800
pubmed: 16411206
J Clin Oncol. 2013 Aug 20;31(24):3034-43
pubmed: 23857966
J Clin Oncol. 2017 Nov 20;35(33):3781-3787
pubmed: 28968169
Pediatr Hematol Oncol. 2013 Apr;30(3):170-7
pubmed: 23484903
Clin Cancer Res. 2018 Dec 15;24(24):6142-6149
pubmed: 30093449
Cancer Med. 2023 Jan;12(2):1532-1539
pubmed: 35950293
Oncotarget. 2017 Apr 18;8(32):52445-52456
pubmed: 28881742
J Clin Oncol. 2007 Feb 1;25(4):362-9
pubmed: 17264331
Pediatr Blood Cancer. 2014 May;61(5):833-9
pubmed: 24249672
Cancer Discov. 2014 Nov;4(11):1326-41
pubmed: 25186949
Oncotarget. 2017 Sep 28;8(69):113418-113430
pubmed: 29371919
J Clin Oncol. 2006 Feb 1;24(4):563-70
pubmed: 16446328